康辰药业 (603590.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

21.2x

Market Cap

CNY 4.79B

MomentumView details →

1D Return

−6.49%

YTD Return

−24.45%

RSI (14)

42.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

21.2x

Market Cap

CNY 4.79B

RSI (14)

42.8

MomentumView details →

1D Return

−6.49%

YTD Return

−24.45%

ProfitabilityView details →

Gross Margin

89.84%

Net Margin

18.38%

EBITDA Margin

25.77%

ROE (TTM)

5.24%

ROA (TTM)

4.14%

Asset Turnover

0.22x

GrowthView details →

Revenue YoY

+9.52%

EPS YoY

+282.79%

FCF YoY

+913.68%

Revenue CAGR 3Y

+1.83%

EPS CAGR 3Y

+17.33%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.10x

Current Ratio

3.05x

Quick Ratio

2.91x

Div Yield

1.17%

Div Rate

CNY 0.35

Div Growth 1Y

−41.67%

Financials snapshotView financials →

Revenue (TTM)

917.99M

Net Income (TTM)

168.68M

Op. CF (TTM)

167.79M

Latest newsMore news →

Kangchen Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 95.7226 million yuan, up 5.14% year-on-year.10d ago

Similar companies

ACADIA Pharmaceuticals Inc.ACAD 科兴制药688136.SH 三力制药603439.SH Celcuity Inc.CELC Edgewise Therapeutics, Inc.EWTX Jacobio Pharmaceuticals Group Co., Ltd.01167.HK Find similar companies →

Latest newsMore news →

Kangchen Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 95.7226 million yuan, up 5.14% year-on-year.10d ago